Citadel Securities Starts Human Genome Sciences (HGSI) at Add; Benlysta Launch Expectations Set Achievable Hurdle
Tweet Send to a FriendGet Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HGSI Now!
Citadel Securities initiates coverage on Human Genome Sciences (NASDAQ: HGSI) with an Add. PT $25.00.
Citadel analyst says, "We believe conservative launch expectations for Benlysta set an achievable hurdle, and we anticipate shares will gain traction during 2H11 as the launch progresses. Notably, we anticipate significant revenue contribution from the drug to begin in 2012, and believe investors should focus on initial leading indicators, such as trends in the number of patient benefit verifications submitted to Benlysta Gateway, during the early stages of the launch. Additionally, we believe investors and the Street are singularly focused on Benlysta and have attributed little, if any, value to the company’s pipeline. The opportunity that we see for investors is potential upside from the “hidden value” of HGSI’s pipeline."
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $15.81 yesterday, with a 52 week range of $15.00-$30.48.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Citadel analyst says, "We believe conservative launch expectations for Benlysta set an achievable hurdle, and we anticipate shares will gain traction during 2H11 as the launch progresses. Notably, we anticipate significant revenue contribution from the drug to begin in 2012, and believe investors should focus on initial leading indicators, such as trends in the number of patient benefit verifications submitted to Benlysta Gateway, during the early stages of the launch. Additionally, we believe investors and the Street are singularly focused on Benlysta and have attributed little, if any, value to the company’s pipeline. The opportunity that we see for investors is potential upside from the “hidden value” of HGSI’s pipeline."
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $15.81 yesterday, with a 52 week range of $15.00-$30.48.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- WallachBeth Capital Starts NuVasive (NUVA) at Buy
- Avondale Partners Starts Tractor Supply Company (TSCO) at Market Outperform
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
